PD907 - “EVALUATION AND INVESTIGATION OF FACTORS AFFECTING BODY COMPOSITION IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS: A SYSTEMATIC REVIEW OF EPIDEMIOLOGICAL STUDIES.”

Linked sessions

PD907

“EVALUATION AND INVESTIGATION OF FACTORS AFFECTING BODY COMPOSITION IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS: A SYSTEMATIC REVIEW OF EPIDEMIOLOGICAL STUDIES.”

E. ILIADOU1,*, M. KARAGIANNIDOU1, I. XINIAS2, E. HATZIAGOROU3, C. N. KATSAGONI4

1Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 2Third Pediatric Department, Hippokration Hospital, , 3Cystic Fibrosis Unit, 3rd Pediatric Dept, Hippokration Hospital, 4Department of Nutritional Sciences & Dietetics, International Hellenic University,, Thessaloniki, Greece

 

Rationale: Body Mass Index (BMI) is commonly used in children and adolescents with cystic fibrosis (CF) to assess nutritional status. However, it has important limitations, as it does not differentiate between fat mass (FM) and fat-free mass (FFM). This study aimed to systematically review and explore the factors influencing body composition (FM and FFM) in patients with CF.

Methods: A systematic literature search was conducted in PubMed and Google Scholar (up to February 2025) to identify eligible studies. Inclusion criteria included: (1) only observational studies published in English, with or without drug administration,(2) assessing the body composition of patients (2-18 y) with CF,(3) patients had to be clinically stable,(4) assessment of body composition using BIA, DXA, or skinfold thickness. PRISMA 2020 and MOOSE guidelines were followed, guided by the SWiM standard. Study quality was evaluated using the Newcastle-Ottawa Scale. A predefined protocol was submitted to Prospero ID: CRD420250652610.

Results: Twenty-three studies met the inclusion criteria, including 857 patients with CF (3–18 y.) and 300 healthy controls. Eight studies reported lower FM and FFM Z-scores in participants with CF despite normal BMI. Four studies showed positive associations between FM/FFM and resting energy expenditure, while two reported beneficial effects of CFTR modulators on FM/FFM. No significant differences in FM or FFM were observed in nine case–control studies.

Image:



 

Conclusion: Patients with CF appear to have lower FM and FFM compared with healthy populations, despite normal BMI. REE and CFTR modulator therapy appear to positively influence body composition in this group.

References:  

Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic Fibrosis Pulmonary Guidelines. Am J Respir Crit Care Med [Internet]. 2009 Nov 1;180(9):802–8.

Disclosure of Interest: None declared